| P50 | author | Helen L. Maddock | Q54397602 |
| | Hardip Sandhu | Q42976086 |
| P2093 | author name string | Helen Maddock | |
| | Hardip Sandhu | |
| P2860 | cites work | Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis | Q57267054 |
| | Childhood cancer survival in Europe and the United States | Q58218213 |
| | Serum microRNAs are promising novel biomarkers | Q21144238 |
| | miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 |
| | MicroRNA genes are transcribed by RNA polymerase II | Q24562649 |
| | Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia | Q24599829 |
| | The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease | Q24606673 |
| | Circulating microRNAs are new and sensitive biomarkers of myocardial infarction | Q24606701 |
| | Exosomes from human saliva as a source of microRNA biomarkers | Q24614806 |
| | MicroRNA dysregulation in diabetic ischemic heart failure patients | Q24618462 |
| | The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation | Q24650204 |
| | MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation | Q24650539 |
| | Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 |
| | Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 |
| | C-reactive protein: a critical update | Q24672855 |
| | A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure | Q24673535 |
| | Perturbation of microRNAs in rat heart during chronic doxorubicin treatment | Q27335046 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu | Q27851435 |
| | BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review | Q27851568 |
| | Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Identification of tissue-specific microRNAs from mouse | Q27860892 |
| | Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells | Q27860960 |
| | MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 |
| | MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice | Q28115423 |
| | Lipid peroxidation-DNA damage by malondialdehyde | Q28138111 |
| | The initial clinical trial of nitrogen mustard | Q28189888 |
| | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| | Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity | Q28212034 |
| | Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes | Q28241500 |
| | Signalling through the lipid products of phosphoinositide-3-OH kinase | Q28241516 |
| | MicroRNA expression in zebrafish embryonic development | Q28253126 |
| | Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity | Q28255255 |
| | Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis | Q34659375 |
| | Smart drugs: tyrosine kinase inhibitors in cancer therapy | Q34710595 |
| | Role of miR-1 and miR-133a in myocardial ischemic postconditioning | Q34732584 |
| | Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. | Q34746933 |
| | Comprehensive thermodynamic analysis of 3' double-nucleotide overhangs neighboring Watson-Crick terminal base pairs | Q34766941 |
| | The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl | Q34944847 |
| | Plasma miR-208 as a biomarker of myocardial injury | Q34998594 |
| | Rational drug design | Q35008284 |
| | Doxorubicin-induced cardiac mitochondrionopathy | Q35217039 |
| | Extracellular microRNA: a new source of biomarkers | Q35417685 |
| | Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy | Q35578778 |
| | Serum troponins as biomarkers of drug-induced cardiac toxicity | Q35624619 |
| | A complex system of small RNAs in the unicellular green alga Chlamydomonas reinhardtii | Q35783043 |
| | Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice | Q35796850 |
| | Current treatment options for endometrial cancer | Q35843726 |
| | Iron trafficking in the mitochondrion: novel pathways revealed by disease. | Q35940415 |
| | Inhibition of miR-15 protects against cardiac ischemic injury | Q35967093 |
| | Taxol stabilizes microtubules in mouse fibroblast cells | Q36360499 |
| | Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function | Q36378477 |
| | Genomics of microRNA. | Q36381610 |
| | Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis | Q36384467 |
| | Serum chemical biomarkers of cardiac injury for nonclinical safety testing | Q36409457 |
| | Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction | Q36503183 |
| | Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic | Q36517425 |
| | p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor | Q36767887 |
| | miRNAs at the heart of the matter | Q36785011 |
| | Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 |
| | Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. | Q36836161 |
| | Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review | Q36870241 |
| | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib | Q37098098 |
| | Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics | Q37203741 |
| | MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. | Q37328435 |
| | Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron | Q37421187 |
| | The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 |
| | Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia | Q28259733 |
| | Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction | Q28264011 |
| | Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia | Q28273146 |
| | A translational study of circulating cell-free microRNA-1 in acute myocardial infarction | Q28275588 |
| | miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells | Q28278471 |
| | Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart | Q28279009 |
| | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| | Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2 | Q28295844 |
| | The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 | Q28295943 |
| | Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma | Q28297805 |
| | Oxidative mechanisms in the toxicity of metal ions | Q28301127 |
| | Dasatinib: a new step in molecular target therapy | Q28307556 |
| | Mitochondrial regulation of superoxide by Ca2+: An alternate mechanism for the cardiotoxicity of doxorubicin | Q28323621 |
| | Risk factors for doxorubicin-induced congestive heart failure | Q28328220 |
| | Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood | Q28334880 |
| | Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma | Q28370603 |
| | Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report | Q28374315 |
| | Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 |
| | MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts | Q28511032 |
| | An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133 | Q28513095 |
| | Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 |
| | Control of stress-dependent cardiac growth and gene expression by a microRNA | Q28587851 |
| | Regulation of mRNA translation and stability by microRNAs | Q29547304 |
| | Caspases: enemies within | Q29547315 |
| | Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis | Q29547607 |
| | Control of translation and mRNA degradation by miRNAs and siRNAs | Q29614239 |
| | Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity | Q29614981 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs | Q29618428 |
| | RNA polymerase III transcribes human microRNAs | Q29618698 |
| | A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance | Q29619547 |
| | MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure | Q29619548 |
| | Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis | Q29619873 |
| | MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis | Q30495845 |
| | Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study | Q31419232 |
| | Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis | Q33397113 |
| | Cardiotoxicity of the antiproliferative compound fluorouracil | Q33611917 |
| | Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure | Q47785101 |
| | BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity | Q48203821 |
| | 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? | Q49145699 |
| | Clinical evaluation of adriamycin, a new antitumour antibiotic | Q49203313 |
| | Pros and cons of high-sensitivity assays for cardiac troponin. | Q51315823 |
| | MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction | Q51652483 |
| | Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis | Q52498584 |
| | PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. | Q53561943 |
| | Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. | Q54323561 |
| | Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. | Q54356342 |
| | Assessment of plasma miRNAs in congestive heart failure. | Q54397399 |
| | Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. | Q54408211 |
| | Circulating microRNAs in patients with coronary artery disease. | Q54421687 |
| | MiR423-5p as a circulating biomarker for heart failure. | Q54439825 |
| | Urinary exosomes. | Q55316628 |
| | Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1 | Q57085792 |
| | Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro | Q33614685 |
| | Detection of anthracycline-induced cardiotoxicity. | Q33711376 |
| | MicroRNA-15b modulates cellular ATP levels and degenerates mitochondria via Arl2 in neonatal rat cardiac myocytes | Q33717662 |
| | Oxidative stress inhibits apoptosis in human lymphoma cells | Q33866794 |
| | Induction of apoptosis by cancer chemotherapy. | Q33876771 |
| | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention | Q33903066 |
| | Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction | Q33917874 |
| | Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity | Q33971055 |
| | Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Q33997854 |
| | Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway | Q34062716 |
| | Gene expression profiling in whole blood of patients with coronary artery disease | Q34070557 |
| | Measurement of cardiac troponins | Q34093775 |
| | The peripheral blood mononuclear cell microRNA signature of coronary artery disease | Q34104103 |
| | Long-term chemotherapy-related cardiovascular morbidity | Q34119341 |
| | Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure | Q34139611 |
| | Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review | Q34179238 |
| | Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage | Q34189929 |
| | Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia | Q34205638 |
| | Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia | Q34235776 |
| | Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease | Q34288063 |
| | Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells | Q34353519 |
| | The taxoids. Comparative clinical pharmacology and therapeutic potential | Q34456149 |
| | Biomarkers of cardiovascular disease: molecular basis and practical considerations | Q34526561 |
| | The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics | Q34551578 |
| | Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies | Q34563378 |
| | An anniversary for cancer chemotherapy | Q34569189 |
| | EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution | Q34649430 |
| | Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins | Q37474816 |
| | Cardiotoxicity induced by tyrosine kinase inhibitors | Q37593059 |
| | Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives | Q37756356 |
| | Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity | Q37949829 |
| | Therapeutic applications of PI3K inhibitors in cardiovascular diseases | Q38089742 |
| | Phosphoinositide 3-kinases: a conserved family of signal transducers | Q38556727 |
| | Metabolism of oxazaphosphorines | Q39649226 |
| | Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs | Q39912452 |
| | p53-mediated activation of miRNA34 candidate tumor-suppressor genes. | Q40102003 |
| | DNA damage is an early event in doxorubicin-induced cardiac myocyte death | Q40299796 |
| | Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice | Q40591772 |
| | Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis | Q40697544 |
| | High-dose ifosfamide is associated with severe, reversible cardiac dysfunction | Q40867037 |
| | Cardiac toxicity 4 to 20 years after completing anthracycline therapy | Q41142694 |
| | MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation | Q41166615 |
| | Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans | Q41412919 |
| | Promotion of microtubule assembly in vitro by taxol | Q41461193 |
| | Anthracycline-induced cardiotoxicity in children and young adults | Q41741113 |
| | Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies | Q42163806 |
| | Acute arrhythmogenicity of doxorubicin administration | Q42219140 |
| | Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity | Q42253680 |
| | Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. | Q42279363 |
| | Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect | Q42280040 |
| | Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity? | Q42280941 |
| | Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer | Q42288584 |
| | Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. | Q42541832 |
| | Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 |
| | Vitamin e and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia | Q42641741 |
| | erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells | Q42807469 |
| | Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib | Q43241611 |
| | The impact of childhood cancer on the United States and the world | Q43489405 |
| | Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity | Q43560510 |
| | Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction | Q43910722 |
| | Preliminary clinical screening with daunorubicin in lung cancer | Q44036177 |
| | N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? | Q44090143 |
| | Inter-strand crosslinking of DNA by nitrogen mustard | Q44095967 |
| | Effects of 5-fluorouracil on globin mRNA synthesis in murine erythroleukemia cells | Q44164136 |
| | Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway | Q44367233 |
| | Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration | Q44418470 |
| | Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction | Q45218584 |
| | The relationship between cell membrane damage and lipid peroxidation under the condition of hypoxia-reoxygenation: analysis of the mechanism using antioxidants and electron transport inhibitors. | Q45944694 |
| | Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 |
| | Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib | Q46348807 |
| | Evaluation of H-FABP as a marker of ongoing myocardial damage using hGH transgenic mice | Q46606457 |
| | Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor | Q46665977 |
| | BNP as a marker of the heart failure in the treatment of imatinib mesylate | Q46876178 |
| | Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincr | Q47569950 |
| | Elevated B-type natriuretic peptide levels after anthracycline administration | Q47685522 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| | biomarker | Q864574 |
| P304 | page(s) | 377-400 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Clinical Science | Q372419 |
| P1476 | title | Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury | |
| P478 | volume | 126 | |